Viatris Clinical Trials: 716 Led Studies

Archive historyOct 2022 to Jun 2026

52 recorded changes across Viatris trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 15 of these trials. One is shown below.

Enrollment changeEnrollment grew to 25,000 from 14,000NCT04957719 · recorded 1 Jun 2026

Track to read them

+48 more recorded changes · Track a drug to see every change the night it lands

Start tracking drugs

Most active programmes

The drugs appearing most often across Viatris's recently active trials. Comparator arms are excluded.

Cenerimod9 trials
Selatogrel8 trials
MR-130A-01 Transdermal patch4 trials
Pravastatin4 trials
ACT-2464753 trials
Verapamil Hydrochloride Extended-Release Capsules, 300 mg3 trials

Upcoming readouts

Next primary completion dates among Viatris's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Nov 2026Investigating Ovulation Inhibition for Use as a ContraceptivePhase 2
Aug 2029LUMIOS: A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis …Phase 3

Top therapeutic areas

Conditions studied most often across Viatris's recently active trials.

Lupus Erythematosus, Systemic4 trials
Acute Myocardial Infarction2 trials
Contraception2 trials
Systemic Lupus Erythematosus2 trials
Hepatic Impairment2 trials
Dry Eye2 trials

Viatris trials

The 50 most significant of Viatris's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary SyndromeNCT07615868Selatogrel	Phase 1	Locked · track to reveal	OngoingRecruiting	20 est.	Oct 2026
OPUS-2A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusNCT05672576Cenerimod	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	451 est.	31 Oct 2026
OPUS-1A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusNCT05648500Cenerimod	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	470 est.	31 Oct 2026
Investigating Ovulation Inhibition for Use as a ContraceptiveNCT07365904MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	30 Nov 2026
SOS-AMISelatogrel Outcome Study in Suspected Acute Myocardial InfarctionNCT04957719Selatogrel	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	25,000 est.	Dec 2026
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing PotentialNCT06672016Transdermal system containing progestin	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	1,630 est.	May 2027
OPUS OLELong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusNCT06475742Cenerimod	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	680 est.	May 2028
LUMIOSA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentNCT07201129Cenerimod	Phase 3	Locked · track to reveal	OngoingRecruiting	300 est.	Aug 2029
A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male ParticipantsNCT07301723Cenerimod (oral)	Phase 1	Locked · track to reveal	Completed	6 est.	18 Mar 2026
A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy ParticipantsNCT07133191Selatogrel	Phase 1	Locked · track to reveal	Completed	32 est.	5 Nov 2025
Study to Evaluate the Effectiveness of Legalon®NCT05051527Legalon® 140 mg	—	Not yet scored	Completed	362 est.	31 Oct 2024
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of CenerimodNCT04819464Cenerimod	Phase 1	Locked · track to reveal	Completed	24 est.	18 Aug 2024
IC/BPSReal-world Evidence Study on CystistatNCT05544695intravesical sodium hyaluronate (Cystistat®)	—	Not yet scored	Completed	74 est.	29 Jul 2024
A Study Evaluating the Safety of the Nasal PumpNCT06329687Tyrvaya Nasal Pump	Phase 4	Locked · track to reveal	StoppedTerminated	5 est.	28 Feb 2024
Dose-finding Study of MR-130A-01 Contraceptive Transdermal PatchNCT06048536MR-130A-01 Transdermal patch	Phase 2	Locked · track to reveal	Completed	168 est.	18 Jan 2024
Phase 4 Study Evaluating the Safety of the Nasal Guide With TyrvayaNCT05918406Nasal Guide	Phase 4	Locked · track to reveal	Completed	30 est.	18 Aug 2023
The Effect of Severe Kidney Impairment on Cenerimod PharmacokineticsNCT05004311Cenerimod	Phase 1	Locked · track to reveal	Completed	16 est.	27 Jul 2023
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic KeratopathyNCT04957758OC-01 (varenicline) nasal spray 1.2 mg/ml	Phase 2	Locked · track to reveal	Completed	113 est.	27 Jan 2023
To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.NCT04255277Combined oral contraceptives (COC)	Phase 1	Locked · track to reveal	Completed	97 est.	14 Sept 2021
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusNCT03742037Cenerimod 0.5 mg	Phase 2	Locked · track to reveal	Completed	427 est.	31 Aug 2021
A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy SubjectsNCT04557280Selatogrel	Phase 1	Locked · track to reveal	Completed	24 est.	19 Dec 2020
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsNCT04406896Selatogrel	Phase 1	Locked · track to reveal	Completed	24 est.	23 Oct 2020
Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian SubjectsNCT04052360Cenerimod	Phase 1	Locked · track to reveal	Completed	20 est.	29 Oct 2019
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsNCT03430661ACT-246475	Phase 1	Locked · track to reveal	Completed	77 est.	20 May 2019
A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy SubjectsNCT03814200ACT-246475	Phase 1	Locked · track to reveal	Completed	14 est.	12 Feb 2019
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart AttackNCT03487445Selatogrel 8 mg	Phase 2	Locked · track to reveal	Completed	48 est.	10 Nov 2018
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery DiseaseNCT03384966Selatogrel	Phase 2	Locked · track to reveal	Completed	346 est.	18 Aug 2018
A Study to Evaluate ACT-246475 Fate in Healthy Male SubjectsNCT03593278ACT-246475	Phase 1	Locked · track to reveal	Completed	6 est.	5 Aug 2018
A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the BodyNCT03173625AC-076 for s.c. administration	Phase 1	Locked · track to reveal	Completed	72 est.	15 Apr 2017
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus ErythematosusNCT02472795Cenerimod	Phase 1	Locked · track to reveal	Completed	105 est.	23 Jan 2017
A Study to Evaluate Cenerimod in Healthy Male SubjectsNCT02914223Cenerimod	Phase 1	Locked · track to reveal	Completed	6 est.	1 Dec 2016
Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441NCT02479204ACT-334441 2 mg	Phase 1	Locked · track to reveal	StoppedTerminated	10 est.	1 May 2016
Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate TabletsNCT00650520BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg	Phase 1	Locked · track to reveal	Completed	119 est.	Jul 2007
Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mgNCT00649480BALSALAZIDE DISODIUM CAPSULES, 750 MG	Phase 1	Locked · track to reveal	Completed	60 est.	Feb 2007
Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mgNCT00650403Paroxetine hydrochloride 40 mg tablet	Phase 1	Locked · track to reveal	Completed	66 est.	Dec 2006
Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mgNCT00649636Fluoxetine Capsules 40 mg	Phase 1	Locked · track to reveal	Completed	32 est.	Apr 2006
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mgNCT00648050Verapamil Hydrochloride Extended-Release Capsules, 300 mg	Phase 1	Locked · track to reveal	Completed	72 est.	Mar 2006
Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mgNCT00647959Doxycycline Tablets, 150mg	Phase 1	Locked · track to reveal	Completed	36 est.	Mar 2006
Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mgNCT00649805Verapamil Hydrochloride Extended-Release Capsules, 300 mg	Phase 1	Locked · track to reveal	Completed	24 est.	Jan 2006
Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mgNCT00649272Oxybutynin Chloride Extended-Release Tablets, 15 mg	Phase 1	Locked · track to reveal	Completed	80 est.	Jan 2006
Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mgNCT00648401Verapamil Hydrochloride Extended-Release Capsules, 300 mg	Phase 1	Locked · track to reveal	Completed	24 est.	Jan 2006
Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mgNCT00647621Extended Phenytoin Sodium Capsules 100 mg	Phase 1	Locked · track to reveal	Completed	72 est.	Dec 2005
Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mgNCT00649155Ciprofloxacin Extended-Release Tablets 500 mg	Phase 1	Locked · track to reveal	Completed	36 est.	Nov 2005
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mgNCT00647608Propranolol Hydrochloride Extended-Release Capsules 160 mg	Phase 1	Locked · track to reveal	Completed	98 est.	Oct 2005
Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mgNCT00649662Ciprofloxacin Extended-Release Tablets 1000 mg	Phase 1	Locked · track to reveal	Completed	36 est.	Oct 2005
Fed Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mgNCT00649987Albuterol Sulfate Extended-Release Tablets 8 mg	Phase 1	Locked · track to reveal	Completed	21 est.	Oct 2005
Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mgNCT00650351Ciprofloxacin Extended-Release Tablets 1000 mg	Phase 1	Locked · track to reveal	Completed	35 est.	Oct 2005
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mgNCT00647816Propranolol Hydrochloride Extended-Release Capsules 160 mg	Phase 1	Locked · track to reveal	Completed	100 est.	Sept 2005
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μgNCT00648700Levothyroxine Sodium Tablets 300 μg	Phase 1	Locked · track to reveal	Completed	32 est.	Sept 2005
Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mgNCT00648180Doxycycline Monohydrate Tablets 100 mg	Phase 1	Locked · track to reveal	Completed	36 est.	Aug 2005

View all trials716

OPUS-2: A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Phase 3Active, not recruitingNCT05672576 ↗

Primary completion: Oct 2026; estimated
Enrollment: 451; estimated
Start: Jun 2023; Viatris Innovation GmbH

Conditions

Lupus Erythematosus, Systemic

Interventions

Cenerimod
Placebo

Brief summary

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Mar 2026

Status change · 1

Enrollment change · 1

Completion date move · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

OPUS-1: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Phase 3Active, not recruitingNCT05648500 ↗

Primary completion: Oct 2026; estimated
Enrollment: 470; estimated
Start: Dec 2022; Viatris Innovation GmbH

Conditions

Lupus Erythematosus, Systemic

Interventions

Cenerimod
Placebo

Brief summary

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Phase 3Active, not recruitingNCT06672016 ↗

Primary completion: May 2027; estimated
Enrollment: 1,630; estimated
Start: Jan 2025; Mylan Pharmaceuticals Inc

Conditions

Female Contraception

Interventions

Transdermal system containing progestin

Brief summary

The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Status change · 2

Completion date move · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

OPUS OLE: Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Phase 3Enrolling by invitationNCT06475742 ↗

Primary completion: May 2028; estimated
Enrollment: 680; estimated
Start: Jul 2024; Viatris Innovation GmbH

Conditions

Lupus Erythematosus, Systemic

Interventions

Cenerimod

Brief summary

The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus. The main questions it aims to answer are: * Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2025

Completion date move · 1

Status change · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

LUMIOS: A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Phase 3RecruitingNCT07201129 ↗

Primary completion: Aug 2029; estimated
Enrollment: 300; estimated
Start: Feb 2026; Viatris Innovation GmbH

Conditions

Nephritis, Lupus
Lupus Erythematosus, Systemic

Interventions

Cenerimod
Placebo

Brief summary

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants

Phase 1CompletedNCT07301723 ↗

Primary completion: Mar 2026; actual
Enrollment: 6; estimated
Start: Dec 2025; Viatris Innovation GmbH

Conditions

Healthy Subjects

Interventions

Cenerimod (oral)
14C-Cenerimod (i.v.)

Brief summary

The goal of this clinical trial is to learn about the absolute bioavailability of cenerimod in healthy participants. It will also provide information about the safety of cenerimod. Participants will receive one tablet with cenerimod, followed by an intravenous (i.v.) infusion with a 14C-radiolabeled cenerimod…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

Phase 1CompletedNCT07133191 ↗

Primary completion: Nov 2025; actual
Enrollment: 32; estimated
Start: Oct 2025; Viatris Innovation GmbH

Conditions

Healthy Volunteers

Interventions

Selatogrel
Matching placebo

Brief summary

This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of selatogrel following a single dose in healthy Japanese and Caucasian participants. Pharmacokinetics is the study of…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jan 2026

Completion date move · 2

Status change · 2

Enrollment change · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

Phase 2CompletedNCT04957758 ↗

Primary completion: Jan 2023; actual
Enrollment: 113; estimated
Start: Jun 2021; Oyster Point Pharma, Inc.

Conditions

Neurotrophic Keratopathy

Interventions

OC-01 (varenicline) nasal spray 1.2 mg/ml
Placebo (vehicle) nasal spray

Brief summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for mean change from baseline in corneal fluorescein staining in subjects with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Oct 2023

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Viatris drugs to see every change the night it lands.

Start tracking drugs

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Phase 1CompletedNCT04255277 ↗

Primary completion: Sept 2021; actual
Enrollment: 97; estimated
Start: Jan 2020; Viatris Innovation GmbH

Conditions

Healthy Subjects

Interventions

Combined oral contraceptives (COC)
Moxifloxacin 400mg
Cenerimod 0.5 mg
Cenerimod 4 mg
Charcoal, activated
Matching Placebo

Brief summary

This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in healthy male and female participants. Participants will be randomly assigned to one of…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

Phase 1CompletedNCT00649805 ↗

Primary completion: Jan 2006; actual
Enrollment: 24; estimated
Start: Jan 2006; Mylan Pharmaceuticals Inc

Conditions

Healthy

Interventions

Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Verelan® PM Extended-Release Capsules, 300 mg

Brief summary

The objective of this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following by a single, oral 300 mg (1 x 300 mg) dose administration sprinkled on one tablespoon of applesauce under fasting conditions.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.